Skip to main content
Category

Press Releases

Avails Medical’s eQUANT paper ‘Novel electronic biosensor for automated inoculum preparation to accelerate antimicrobial susceptibility testing’ published in Scientific Reports

By Press Releases

MENLO PARK, Calif., June 1, 2021 /PRNewswire/ – Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) announced today the publication of a new peer-reviewed paper on its eQUANTTM system and technology in Scientific Reports.

The eQUANTTM – a novel instrument utilizing electrical biosensors – produces a standardized inoculum equivalent to a 0.5 McFarland directly from positive blood cultures. The proof-of-concept study demonstrates that eQUANTTM inocula prepared from clinically significant species of Enterobacterales were comparable to 0.5 McFarland inocula generated from bacterial colonies in both CFU/ml concentration and performance in antimicrobial susceptibility testing, with ≧95% essential and categorical agreement for VITEK2 and disk diffusion. The eQUANTTM, combined with a rapid, direct from positive blood culture identification technique, can allow the clinical laboratory to begin antimicrobial susceptibility testing using a standardized inoculum approximately 2-3 hours after a blood culture flags positive. This has the potential to improve clinical practice by accelerating conventional antimicrobial susceptibility testing and the resulting targeted antibiotic therapy.

“eQUANTTM will eliminate the current need for time consuming 18-24 hour bacterial Petri dish cultures and enable standard AST to be initiated one day earlier”, said Meike Herget, PhD, CTO of Avails Medical.

“Accelerating antibiotic susceptibility testing for blood stream infections is key to reduce patient mortality and to de-escalate antibiotic therapy from a costly broad spectrum and empiric one to a targeted and lower cost therapy. With eQUANTTM we are addressing the holy grail of timely blood stream infection diagnosis by allowing AST directly from a patient positive blood culture, saving time and lives. We are excited to be providing clinical laboratories with a simple though powerful new device that will fit seamlessly within a clinical lab’s workflow and enable timely and highly accurate AST results. Avails will be challenging the technology in our upcoming clinical study trials”, said Dr. Herget.

About eQUANTTM

Avails eQUANTTM technology will enable a single-step automated 0.5 McFarland preparation (in as fast as 40 minutes) directly from positive blood culture (PBC), removing 18+ hours from workflow by eliminating the need for subcultures. eQUANTTM will enable legacy AST systems to be used directly from PBC. In addition eQUANTTM will also allow for direct-from-PBC disk diffusion. The eQUANTTM system is currently being evaluated in clinical studies.

Citation

Putney, S., Theiss, A.H., Rajan, N.K. et al. Novel electronic biosensor for automated inoculum preparation to accelerate antimicrobial susceptibility testing. Sci Rep 11, 11360 (2021). https://doi.org/10.1038/s41598-021-90830-2

About Avails Medical Inc.

Avails Medical, Inc., a privately held company, was founded in 2013 to help fight one of today’s biggest global health threats – antibiotic resistance. Founded by a team of Stanford University alums, the Avails all-electrical technology platform is designed to significantly reduce the amount of time required to obtain the reliable antibiotic susceptibility data required to enable accurate therapy decisions. Avails’ electronic biosensor technology is designed to improve speed and accuracy in pathogen quantification and susceptibility testing directly from human specimens by eliminating crude, time-consuming culturing steps.

CONTACT:
Avails Medical
press@availsmedical.com

Avails Medical awarded $2.5M in CARB-X funding for the development of its rapid antibiotic susceptibility testing device to identify the most effective antibiotic therapy

By Press Releases

MENLO PARK, Calif., February 1, 2021 /PRNewswire/ — Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) announced today it was awarded up to $2.5M in non-dilutive funding from CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. CARB-X is a global non-profit partnership based at Boston University School of Law and dedicated to funding the development of new antibiotics, vaccines, diagnostics and other products to address antibiotic-resistant bacteria.

Funds will support the development of Avails Medicals’ eAST technology, a fully electrical antibiotic susceptibility testing (AST) device to significantly reduce the time-to-results and enable health care providers to rapidly determine the most effective antibiotic treatment for patients with severe bloodstream infections, especially those involving multidrug-resistant pathogens.

The company will be eligible for an additional $14.7 million in non-dilutive funding from Carb-X upon successful completion of milestones.

“Speed is critical in the treatment of serious bacterial infections. Every hour delay of effective treatment increases the risk of complications and septic shock”, said Erin Duffy, Chief of Research and Development of CARB-X. “The Avails eAST diagnostic aims to provide phenotypic results within four hours from a positive blood culture which is critical in guiding antibiotic therapy decisions especially in multi-drug resistance infections.”

“Currently, it can take days to identify which antibiotics would be most effective in treating a lethal bacterial infection in the bloodstream,” said Oren Knopfmacher, CEO of Avails Medical. “The faster a clinician can get a clear picture of which antibiotic is most suited to kill the bacteria, the more likely the patient is to survive. We are honored to be recognized for our unique and transforming technology and are thrilled to join the CARB-X family. Fighting antibiotic resistance is our common goal and mission.”

About Avails Medical Inc.
Avails Medical, Inc., a privately held company, was founded in 2013 to help fight one of today’s biggest global health threats – antibiotic resistance. Founded by a team of Stanford University alums, the Avails all-electrical technology platform is designed to significantly reduce the amount of time required to obtain the reliable antibiotic susceptibility data required to enable accurate therapy decisions. Avails’ electronic biosensor technology is designed to improve speed and accuracy in pathogen quantification and susceptibility testing directly from human specimens by eliminating crude, time-consuming culturing steps. www.availsmedical.com

About CARB-X
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services, the Wellcome Trust, a global charity based in the UK working to improve health globally, Germany’s Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).  CARB-X is investing up to $480 million from 2016-2022 to support innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics. CARB-X supports the world’s largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X is headquartered at Boston University School of Law. carb-x.org/.

CONTACT:
Avails Medical
Oren Knopfmacher, PhD
press@availsmedical.com

SOURCE Avails Medical, Inc.

Avails Medical, a pioneer in automated, accelerated antibiotic susceptibility testing for septic patients announced today the participation of OMRON VENTURES Co., Ltd. in its current equity financing round

By Press Releases

MENLO PARK, Calif., March 24, 2020 /PRNewswire/ — Avails Medical, a pioneer in automated, accelerated antibiotic susceptibility testing (AST) for septic patients announced today the participation of OMRON VENTURES Co., Ltd. in its current equity financing round.

The current investment round will allow Avails Medical to accelerate the development of its AST product pipeline, including the eQuant system, which was announced at ECCMID 2019. eQuant automates and closes the 24 hour workflow gap between rapid identification (ID) methods and legacy AST systems by providing a standardized inoculum (McFarland) directly from a positive blood culture in as fast as 1 hour. The McFarland standard is required in any conventional AST to ensure accurate results.

“As a leader in automation and healthcare, we are excited to join Avails in the fight against antibiotic resistance. Their revolutionary approach will transform hospital lab workflow and bring it to the 21st century, allowing hospitals to turn their outdated system into rapid ones overnight”, said Tomoko Inoue, CEO of OMRON VENTURES.

“OMRON’s mission to improve lives and contribute to a better society is aligned with Avails’ focus to fight the biggest global health threat – antibiotic resistance,” said Oren Knopfmacher, PhD, CEO and co-founder of Avails Medical. “This collaboration will allow Avails to learn from a true medical visionary and healthcare market leader, and together, collaboratively fight back against the rapid spread of antibiotic resistance.”

About Avails Medical
Avails Medical, Inc., a privately held company, was founded in 2013 to help fight one of today’s biggest global health threats – antibiotic resistance. Founded by a team of Stanford University alums, the Avails technology platform is designed to significantly reduce the amount of time required to obtain the reliable antibiotic susceptibility data required to enable accurate therapy decisions.  Avails’ electronic biosensor technology is designed to improve accuracy in pathogen quantification and susceptibility testing directly from human specimens by eliminating crude, time-consuming culturing steps.

CONTACT: press@availsmedical.com

About OMRON VENTURES
OMRON VENTURES is the venture capital arm of OMRON Corporation and its affiliated companies. Its mission is to create a new world by joining hands with entrepreneurs all over the globe who see things in their own free way, who are unencumbered by conventional practice, and who seriously believe they can change the world. For more information, visit https://www.omron.com/ventures/

SOURCE Avails Medical, Inc.

Avails Medical announcing eQuant, a novel IVD being developed to allow rapid standardized inoculum generation directly from a positive blood culture

By Press Releases

Product integrates to non-rapid commercial AST, antibiotic susceptibility test, systems and dramatically shortens the process.

Menlo Park, Calif., Apr. 11th, 2019 (PRESS RELEASE) — Avails Medical, Inc. (www.availsmedical.com), an in-vitro diagnostics company committed to accelerating time to accurate therapy decisions for septic patients, will unveil its first product, eQuant, at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2019).

eQuant is bridging the gap between rapid identification (ID) methods and legacy AST systems by providing a standardized inoculum (McFarland) directly from a positive blood culture in as fast as 1 hour. The McFarland standard is required in any conventional AST to ensure accurate results. eQuant coined the term “DON’T WAIT FOR THE PLATE” as it is intended to eliminate the time-consuming sub-cultures needed for current McFarland standard preparation. eQuant is in advanced development stages and has already shown 96% correlation to gold standard methods. eQuant could turn any non-rapid commercial AST system directly into a rapid AST solution. It is expected to be the first product in the market to create an automated standardized inoculum directly from positive blood culture.

Avails Medical will be presenting at booth #1.111.

About Avails Medical

Avails Medical, Inc., a privately held company, was founded in 2013 to help fight one of today’s biggest global health threats – antibiotic resistance. Founded by a team of Stanford University alums, the Avails technology platform is designed to significantly reduce the amount of time required to obtain the reliable antibiotic susceptibility data required to enable accurate therapy decisions. Avails’ electronic biosensor technology is designed to improve accuracy in pathogen quantification and susceptibility testing directly from human specimens by eliminating crude, time-consuming culturing techniques.

Media contact: press@availsmedical.com